Bumetanide Tablets, USP, 2 mg, 100-count bottle, Rx only, Manufactured by: Upser-Smith Laborator...

FDA Drug Recall #D-0281-2019 — Class II — September 19, 2018

Recall Summary

Recall Number D-0281-2019
Classification Class II — Moderate risk
Date Initiated September 19, 2018
Status Terminated
Voluntary Voluntary: Firm initiated

Recalling Firm

Firm Upsher Smith Laboratories, Inc.
Location Maple Grove, MN
Product Type Drugs
Quantity 29,080 bottles

Product Description

Bumetanide Tablets, USP, 2 mg, 100-count bottle, Rx only, Manufactured by: Upser-Smith Laboratories, LLC, Maple Grove, MN 55369, NDC 0832-0542-11

Reason for Recall

Failed impurities/ degradation specifications: Product is Out of Specification for an unspecified degradation product.

Distribution Pattern

Nationwide USA, Puerto Rico and Guam

Lot / Code Information

Lot#: 372461, 372952, 372954, 372955, 373624, 374539, Exp 3/31/2020; 375719, 375721, 376684, Exp 5/31/2020

Other Recalls from Upsher Smith Laboratories, Inc.

Recall # Classification Product Date
D-1836-2019 Class II Bexarotene Capsules, 75 mg, 100 capsules per bo... Jul 29, 2019
D-0280-2019 Class II Bumetanide Tablets, USP, 1 mg, 100-count bottle... Sep 19, 2018
D-1255-2014 Class III Oxandrolone Tablets, USP, 10 mg, Rx Only, C-III... Apr 14, 2014
D-127-2013 Class III Divalproex Sodium Delayed-Release Tablets, USP,... Dec 10, 2012
D-160-2013 Class II Propranolol Hydrochloride Extended-release Caps... Nov 20, 2012

Frequently Asked Questions

Nitrosamines are probable human carcinogens — they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.

Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.

Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.

What Should You Do?

Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.